Clinical experience with activated factor VII: Focus on safety aspects

Blood Coagulation and Fibrinolysis

Volumn 9, Issue SUPPL. 1, 1998, Pages

  Roberts, H R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Factor VIIa; Factor VIII

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 7; IMMUNOGLOBULIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

ANAPHYLACTIC SHOCK; ANGINA PECTORIS; ATAXIA; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG SAFETY; HEMOPHILIA A; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT PLANNING;

EID: 0031756987     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Kurczynski EM, Penner JA. Activated prothrombin complex concentrate for patients with factor VIII inhibitors. N Engl J Med 1974; 291:164-167.
2. Gomperts ED, Heisel MA, Hilgartner M, McComb JG. Use of activated prothrombin complex concentrates over multiple surgical episodes in a hemophilic child with an inhibitor. J Pediatr 1983; 102:951-953.
3. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high titer inhibitors. J Clin Invest 1983; 71:1836-1841.
4. Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor dependent initiation of coagulation. Blood 1995; 86:1794-1801.
5. Hoffman M, Monroe DM, Oliver JA, Roberts HR. Platelet activity of high dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99:542-547.
6. Lusher J, Ingerslev J, Roberts HR, Hedner U. Clinical experience with recombinant factor VIIa: a review. Blood Coag Fibrinol 1998; 9:in press.
7. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, et al., for the rFVIIa Study Group. A randomised double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia 1998; in press.
8. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegård J, Holm M, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26 (suppl 1):159-164.
9. Stein SF, Duncan A, Cutler D, Glazer S. Disseminated intravascular coagulation (DIC) in a hemophiliac treated with recombinant factor VIIa [abstract]. Blood 1990; 76:438a.
10. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban R, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113:1930-1937.
11. Bernstein DE, Glazer S, Reddy KR, Squiban P, Bech RM, Roach K, et al. The effect of recombinant factor VIIa (rFVIIa) on the hematological parameters of diffuse intravascular coagulation (DIC) in cirrhotic patients. Hepatology 1996; 23:1-18.
12. Glazer S, Hedner U, Falch JF. Clinical update on the use of recombinant factor VII. Adv Exp Med Biol 1995; 386:163-174.